Is Mounjaro Approved for Weight Loss in the UK?

Step 1: The MHRA licence, the formal approval that makes Mounjaro legal to prescribe for weight loss

Tirzepatide received its UK marketing authorisation from the MHRA for weight management before the NICE process began. That licence covers adults with a BMI at or above 30, or at or above 27 when at least one weight-related condition is present, prediabetes, hypertension, high cholesterol, obstructive sleep apnoea, or cardiovascular disease, among others. The NHS medicines page for tirzepatide sets out the licensed indication plainly if you want the official wording.

Because tirzepatide acts on both GIP and GLP-1 receptors, it differs mechanically from earlier GLP-1 medicines. Appetite falls, gastric emptying slows, and the combined hormonal effect tends to produce greater average weight loss than single-pathway medicines in head-to-head comparisons. That dual action was a central part of the evidence Eli Lilly submitted to the MHRA for approval.

One practical point worth knowing: the licence covers the medicine, but it does not mean every adult in the UK can simply request it. A prescriber still assesses each person individually. The medicine being approved is the start of the process, not the end of it.

Step 2: The NICE recommendation, the evidence review that shaped NHS access

NICE published its appraisal of tirzepatide for weight management (TA1026) on 23 December 2024, updated in September 2025. The committee reviewed the full trial programme, including SURMOUNT-1, which randomised 2,539 adults and found average weight reductions of around 20–21% at the highest dose over 72 weeks, as published in the New England Journal of Medicine.

NICE recommended tirzepatide for NHS use in adults with a BMI of 35 or above and at least one weight-related comorbidity. Thresholds are 2.5 kg/m² lower for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. If less than 5% weight loss has occurred after six months at the highest tolerated dose, the prescriber reviews whether to continue.

NHS rollout is phased. From June 2025 the criteria required a BMI of 40 or above alongside four or more qualifying conditions; from around June 2026 a second cohort with lower BMI became eligible. Access through the NHS also depends on availability at your GP practice, participation in the new prescribing framework is currently optional. Private treatment through a regulated pharmacy sidesteps waiting lists for those who are clinically suitable but cannot access NHS provision, or simply do not want to wait.

Step 3: What the approval covers, and what sits outside it

The licence is specifically for weight management alongside a reduced-calorie diet and increased physical activity. It is not a standalone treatment, and the MHRA has been clear that GLP-1 medicines are not approved for quick or cosmetic weight loss. If you have been searching for more detail on the tirzepatide approval timeline, that distinction matters: the evidence base, the trials, and the regulator's recommendation all point to a medicine used as part of a broader lifestyle programme.

Mounjaro is also licensed for type 2 diabetes, which is a separate indication from weight management. Some people hold both conditions; others are prescribed it solely for weight. If you want a straightforward answer to whether Mounjaro is approved in the UK, the short answer is yes, though the prescriber works out which indication applies and whether the medicine is appropriate for that individual.

For people curious about the approval in the context of other conditions, there is a related question about Mounjaro and obstructive sleep apnoea, that indication has been the subject of clinical trials, and the picture there is evolving separately from the weight-management licence.

Understanding the cost of private treatment is a reasonable next step once the approval question is answered. The Mounjaro cost page covers how private pricing is structured in the UK, what a legitimate price includes, and how the market has shifted since Eli Lilly revised UK list prices in September 2025.

Starting treatment: the prescription process in practice

Mounjaro is a prescription-only medicine. In the UK, the only legal route to it is a prescription issued after a clinical assessment by a qualified prescriber. That is true whether you go through your GP, an NHS specialist service, or a GPhC-registered online pharmacy.

At nume, the process runs as follows. You complete a free online consultation; a GPhC-registered Independent Prescriber reads your answers the same day, a real clinician, not software. Identity is verified by photo ID, and weight is confirmed on a live video call. If the prescriber approves, your treatment is dispatched the same day for orders placed before noon on a working day, arriving the next working day via DPD in plain packaging. Our clinical team is available seven days a week for aftercare questions.

Treatment begins at 2.5 mg. That starting dose is there to let your system adjust, not to produce immediate weight loss, the therapeutic effect builds as the prescriber titrates the dose over subsequent months. Most people find the first few weeks the most demanding in terms of side effects, which tend to be gastrointestinal and usually settle as the body adapts. If you still have questions about whether Mounjaro has been approved for weight loss, a full overview of what to expect is also on the Mounjaro information page.

One brief practical note: if you are planning to start around a bank holiday or payday, it is worth checking dispatch timelines in advance, orders placed after noon or on non-working days are dispatched the next available working day, so a Monday order before noon is usually the most reliable for a Tuesday delivery.

If you have already confirmed Mounjaro is right for you and want to understand the broader landscape of what is available, the weight-loss treatments page sets out all options nume prescribes, with a free consultation as the starting point.